(Q35795156)

10 August 2017

1 reference

title

New formulations of existing antidepressants: advantages in the management of depression (English)

1 reference

10 August 2017

Trevor R Norman

1

1 reference

10 August 2017

James S Olver

series ordinal

2

1 reference

10 August 2017

publication date

1 January 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

18

1 reference

10 August 2017

issue

8

1 reference

10 August 2017

page(s)

505-520

1 reference

Patient compliance to a new enteric-coated weekly formulation of fluoxetine during continuation treatment of major depressive disorder

10 August 2017

cites work

1 reference

12 December 2020

Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative

1 reference

12 December 2020

Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor

1 reference

12 December 2020

Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients

1 reference

12 December 2020

1 reference

12 December 2020

Do some antidepressants work faster than others?

1 reference

12 December 2020

The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer

1 reference

12 December 2020

Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials.

1 reference

12 December 2020

Clinical pharmacokinetics of mirtazapine

1 reference

12 December 2020

Venlafaxine: A Structurally Unique and Novel Antidepressant

1 reference

12 December 2020

Metabolic pathway of paroxetine in animals and man and the comparative pharmacological properties of its metabolites

1 reference

12 December 2020

Double-blind trial with oral versus intravenous clomipramine in primary depression

1 reference

12 December 2020

The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder.

1 reference

12 December 2020

Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea.

1 reference

12 December 2020

Third-generation antidepressants: do they offer advantages over the SSRIs?

1 reference

12 December 2020

Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data.

1 reference

12 December 2020

Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features

1 reference

12 December 2020

Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite

1 reference

12 December 2020

The pharmacologic rationale for the clinical use of antidepressants.

1 reference

12 December 2020

Mirtazapine : A Review of its Pharmacology and Therapeutic Potential in the Management of Major Depression

1 reference

12 December 2020

Treatment approaches to major depressive disorder relapse. Part 2: reinitiation of antidepressant treatment.

1 reference

12 December 2020

Patient compliance with enteric-coated weekly fluoxetine during continuation treatment of major depressive disorder.

1 reference

12 December 2020

Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression.

1 reference

12 December 2020

Mirtazapine: clinical advantages in the treatment of depression

1 reference

12 December 2020

Paroxetine controlled release

1 reference

12 December 2020

Pharmacokinetic optimisation of therapy with newer antidepressants

1 reference

12 December 2020

Drug chirality and its clinical significance

1 reference

12 December 2020

Potential new drug delivery systems for antidepressants: an overview.

1 reference

12 December 2020

Fluoxetine dose and outcome in antidepressant drug trials

1 reference

12 December 2020

Enantiomers' potential in psychopharmacology--a critical analysis with special emphasis on the antidepressant escitalopram

1 reference

12 December 2020

Suicide by antidepressant intoxication identified at autopsy in Vienna from 1991–1997: the favourable consequences of the increasing use of SSRIs

1 reference

12 December 2020

Efficacy of intravenous citalopram compared with oral citalopram for severe depression. Safety and efficacy data from a double-blind, double-dummy trial

1 reference

12 December 2020

Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model

1 reference

12 December 2020

Efficacy of controlled-release paroxetine in the treatment of late-life depression.

1 reference

12 December 2020

Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group

1 reference

12 December 2020

Depresssion--emerging insights from neurobiology

1 reference

12 December 2020

Cardiovascular effects of fluoxetine in depressed patients with heart disease

1 reference

12 December 2020

Pharmacokinetics and biotransformation of mirtazapine in human volunteers

1 reference

12 December 2020

Venlafaxine. A review of its pharmacology and therapeutic potential in depression

1 reference

12 December 2020

Cellular mechanisms in the vulnerability to depression and response to antidepressants

1 reference

12 December 2020

Treatment approaches to major depressive disorder relapse. Part 1: dose increase

1 reference

12 December 2020

Stereochemical determinants of the nature and consequences of drug metabolism

1 reference

12 December 2020

Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association

1 reference

12 December 2020

Classifying depression: should paradigms lost be regained?

1 reference

12 December 2020

Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care

1 reference

12 December 2020

Plasma-level response relationships with fluoxetine and zimelidine

1 reference

12 December 2020

Once-weekly fluoxetine

1 reference

12 December 2020

Exploring treatment alternatives: weekly dosing of fluoxetine for the continuation phase of major depressive disorder

1 reference

12 December 2020

Patient perspectives on once-weekly fluoxetine

1 reference

12 December 2020

Venlafaxine extended-release: a review of its use in the management of major depression

1 reference

12 December 2020

Intravenous mirtazapine in the treatment of depressed inpatients

1 reference

12 December 2020

10.2165/00023210-200418080-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

10 August 2017

1045143690

0 references

1 reference